J Menopausal Med.  2017 Dec;23(3):182-189. 10.6118/jmm.2017.23.3.182.

The Effect of Estrogen Replacement Therapy on Visceral Fat, Serum Glucose, Lipid Profiles and Apelin Level in Ovariectomized Rats

• Babaei P
• Dastras A
• Tehrani BS
• Pourali Roudbaneh S

• KMID: 2400254
• DOI: http://doi.org/10.6118/jmm.2017.23.3.182

Abstract

OBJECTIVES
Ovarian hormones have been shown to regulate body weight, intra-abdominal fat accumulation and plasma level of cytokines. The aim of this study was to investigate the effect of estrogen replacement therapy on visceral adipose tissue, plasma level of apelin, lipid profiles, and glucose in ovariectomized (OVX) rats.
METHODS
Thirty female Wistar rats were divided into OVX (n = 20) and sham (n = 10) groups. OVX rats were subdivided into estrogen replacement therapy (OVX+est; n = 10) receiving 17 β-estradiol valerates (30 µg/kg, s.c., 5 day/week, for eight weeks), and vehicle control group receiving sesame oil same as experiment group (OVX+ses oil; n = 10). After the treatments, all groups were sacrificed and blood samples were collected, visceral fats were taken from the abdominal cavity and weighed immediately. Apelin were measured using enzyme-linked immunosorbent assay kits. Lipid profiles and glucose were measured using the enzymatic colorimetric method. Data were analyzed with one-way analysis of variance and (P < 0.05) determined as the statistical significance level.
RESULTS
After eight weeks, body weight, body mass index (BMI), visceral fat, apelin and lipid profiles (P < 0.01) were increased significantly in OVX rats compared to sham group. Treatment with estrogen leads to significant reduction in body weight and BMI (P < 0.05), there was no significant change in serum apelin level in OVX+est rats compared to OVX+ses.
CONCLUSIONS
These results suggest that estradiol replacement therapy successfully attenuated some of the metabolic syndrome components, and apelin does not probably stand as a mediator of these physiological functions.

Keyword

Apelin; Estrogen replacement therapy; Glucose; Intra-abdominal fat; Rats

MeSH Terms

Abdominal Cavity
Animals
Blood Glucose*
Body Mass Index
Body Weight
Cytokines
Enzyme-Linked Immunosorbent Assay
Estradiol
Estrogen Replacement Therapy*
Estrogens*
Female
Glucose
Humans
Intra-Abdominal Fat*
Methods
Plasma
Rats*
Rats, Wistar
Sesame Oil
Valerates
Cytokines
Estradiol
Estrogens
Glucose
Sesame Oil
Valerates

Reference

1. Davidson LE, Hudson R, Kilpatrick K, Kuk JL, McMillan K, Janiszewski PM, et al. Effects of exercise modality on insulin resistance and functional limitation in older adults: a randomized controlled trial. Arch Intern Med. 2009; 169:122–131.

2. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol. 2013; 216:T17–T36.

3. Paszkowski T, Kłodnicka M. Hormonalna terapia zastępcza. Przegl Menopauzalny. 2007; 2:106–109.

4. Ferrara CM, Lynch NA, Nicklas BJ, Ryan AS, Berman DM. Differences in adipose tissue metabolism between postmenopausal and perimenopausal women. J Clin Endocrinol Metab. 2002; 87:4166–4170.

5. Foster MT, Pagliassotti MJ. Metabolic alterations following visceral fat removal and expansion: Beyond anatomic location. Adipocyte. 2012; 1:192–199.

6. Augoulea A, Mastorakos G, Lambrinoudaki I, Christodoulakos G, Creatsas G. Role of postmenopausal hormone replacement therapy on body fat gain and leptin levels. Gynecol Endocrinol. 2005; 20:227–235.

7. Blake J. Menopause: evidence-based practice. Best Pract Res Clin Obstet Gynaecol. 2006; 20:799–839.

8. Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res. 2002; 57:257–275.

9. Utian WH. Menopause-related definitions. Int Congr Ser. 2004; 1266:133–138.

10. Mattsson C, Olsson T. Estrogens and glucocorticoid hormones in adipose tissue metabolism. Curr Med Chem. 2007; 14:2918–2924.

11. Misso ML, Jang C, Adams J, Tran J, Murata Y, Bell R, et al. Differential expression of factors involved in fat metabolism with age and the menopause transition. Maturitas. 2005; 51:299–306.

12. Pedersen SB, Kristensen K, Hermann PA, Katzenellenbogen JA, Richelsen B. Estrogen controls lipolysis by upregulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution. J Clin Endocrinol Metab. 2004; 89:1869–1878.

13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287:356–359.

14. Cekmez F, Canpolat FE, Pirgon O, Çetinkaya M, Aydinoz S, Suleymanoglu S, et al. Apelin, vaspin, visfatin and adiponectin in large for gestational age infants with insulin resistance. Cytokine. 2011; 56:387–391.

15. Corriveau P, Paquette A, Brochu M, Prud’homme D, Rabasa-Lhoret R, Lavoie JM. Resistance training prevents liver fat accumulation in ovariectomized rats. Maturitas. 2008; 59:259–267.

16. Babaei P, Damirchi A, Hoseini R. The interaction effects of aerobic exercise training and vitamin D supplementation on plasma lipid profiles and insulin resistance in ovariectomized rats. J Exerc Nutrition Biochem. 2015; 19:173–182.

17. Edinger AL, Hoffman TL, Sharron M, Lee B, Yi Y, Choe W, et al. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol. 1998; 72:7934–7940.

18. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998; 251:471–476.

19. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem. 2000; 275:21061–21067.

20. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000; 74:34–41.

21. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993; 136:355–360.

22. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta. 2001; 1538:162–171.

23. Devic E, Paquereau L, Vernier P, Knibiehler B, Audigier Y. Expression of a new G protein-coupled receptor X-msr is associated with an endothelial lineage in Xenopus laevis. Mech Dev. 1996; 59:129–140.

24. Esteve E, Ricart W, Fernández-Real JM. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care. 2009; 32:Suppl 2. S362–S367.

25. Hus-Citharel A, Bouby N, Frugière A, Bodineau L, Gasc JM, Llorens-Cortes C. Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int. 2008; 74:486–494.

26. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003; 84:1162–1172.

27. Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A, et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes. 2007; 115:428–432.

28. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92:347–355.

29. Wei L, Hou X, Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept. 2005; 132:27–32.

30. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes. 2003; 52:268–276.

31. Chapman NA, Dupre DJ, Rainey JK. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. Biochem Cell Biol. 2014; 92:431–440.

32. Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K, et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology. 2007; 148:2690–2697.

33. Babaei P, Mehdizadeh R, Ansar MM, Damirchi A. Effects of ovariectomy and estrogen replacement therapy on visceral adipose tissue and serum adiponectin levels in rats. Menopause Int. 2010; 16:100–104.

34. Damirchi A, Mehdizade R, Ansar MM, Soltani B, Babaei P. Effects of aerobic exercise training on visceral fat and serum adiponectin concentration in ovariectomized rats. Climacteric. 2010; 13:171–178.

35. Saengsirisuwan V, Pongseeda S, Prasannarong M, Vichaiwong K, Toskulkao C. Modulation of insulin resistance in ovariectomized rats by endurance exercise training and estrogen replacement. Metabolism. 2009; 58:38–47.

36. Zoth N, Weigt C, Laudenbach-Leschowski U, Diel P. Physical activity and estrogen treatment reduce visceral body fat and serum levels of leptin in an additive manner in a diet induced animal model of obesity. J Steroid Biochem Mol Biol. 2010; 122:100–105.

37. Zoth N, Weigt C, Zengin S, Selder O, Selke N, Kalicinski M, et al. Metabolic effects of estrogen substitution in combination with targeted exercise training on the therapy of obesity in ovariectomized Wistar rats. J Steroid Biochem Mol Biol. 2012; 130:64–72.

38. Azman A, Khalid BAK, Ima-Nirwana S. The effects of vitamin E on bodyweight and fat mass in intact and ovariectomized female rats. Med J Islamic World Acad Sci. 2001; 14:125–138.

39. Wang JF, Guo YX, Niu JZ, Liu J, Wang LQ, Li PH. Effects of Radix Puerariae flavones on liver lipid metabolism in ovariectomized rats. World J Gastroenterol. 2004; 10:1967–1970.

40. Hoseini R, Damirchi A, Babaei P. Vitamin D increases PPARgamma expression and promotes beneficial effects of physical activity in metabolic syndrome. Nutrition. 2017; 36:54–59.

41. Al-Wahaibi A, Farihah HS, Azian AL, Wan Nazaimoon WM. Effects of ovariectomy on body weight and activity of 11-beta hydroxysteroid dehydrogenase type I In the liver and adipose tissue of rats. Sci J King Faisal Univ. 2008; 9:149–162.

42. Choi SB, Jang JS, Park S. Estrogen and exercise may enhance beta-cell function and mass via insulin receptor substrate 2 induction in ovariectomized diabetic rats. Endocrinology. 2005; 146:4786–4794.

43. Meli R, Pacilio M, Raso GM, Esposito E, Coppola A, Nasti A, et al. Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats. Endocrinology. 2004; 145:3115–3121.

44. Mueller SO, Korach KS. Immortalized testis cell lines from estrogen receptor (ER) alpha knock-out and wild-type mice expressing functional ERalpha or ERbeta. J Androl. 2001; 22:652–664.

45. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, et al. The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors. Eur J Endocrinol. 2004; 150:715–718.

46. Latour MG, Shinoda M, Lavoie JM. Metabolic effects of physical training in ovariectomized and hyperestrogenic rats. J Appl Physiol (1985). 2001; 90:235–241.

47. Ryan AS, Nicklas BJ, Berman DM. Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care. 2002; 25:127–133.

48. D'Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS. Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem. 2005; 280:35983–35991.

49. Sites CK, Brochu M, Tchernof A, Poehlman ET. Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women. Metabolism. 2001; 50:835–840.

50. Munoz J, Derstine A, Gower BA. Fat distribution and insulin sensitivity in postmenopausal women: influence of hormone replacement. Obes Res. 2002; 10:424–431.

51. Sumino H, Ichikawa S, Yoshida A, Murakami M, Kanda T, Mizunuma H, et al. Effects of hormone replacement therapy on weight, abdominal fat distribution, and lipid levels in Japanese postmenopausal women. Int J Obes Relat Metab Disord. 2003; 27:1044–1051.

52. Tchernof A, Desmeules A, Richard C, Laberge P, Daris M, Mailloux J, et al. Ovarian hormone status and abdominal visceral adipose tissue metabolism. J Clin Endocrinol Metab. 2004; 89:3425–3430.

53. Wakatsuki A, Ikenoue N, Okatani Y, Fukaya T. Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol. 2001; 37:425–430.

54. Heinonen MV, Purhonen AK, Miettinen P, Pääkkönen M, Pirinen E, Alhava E, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept. 2005; 130:7–13.

55. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A, et al. Apelin, a newly identified adipokine upregulated by insulin and obesity. Endocrinology. 2005; 146:1764–1771.

56. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005; 107:198–211.

57. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006; 114:544–548.

58. Rittig K, Hildebrandt U, Thamer C, Staiger H, Peter A, Stefan N, et al. Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes. Exp Clin Endocrinol Diabetes. 2011; 119:358–361.

59. Altinkaya SÖ, Nergiz S, Küçük M, Yüksel H. Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014; 176:168–172.

60. Cebeci AN, Guven A, Kuru LI. Perinephric adipose tissue thickness in relation to blood pressure, plasma apelin and C-reactive protein levels in obese adolescents. Minerva Endocrinol. 2016; 41:166–174.

61. Cekmez F, Cekmez Y, Pirgon O, Canpolat FE, Aydinöz S, Metin Ipcioglu O, et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. Eur Cytokine Netw. 2011; 22:32–37.

62. Chang CY, Tsai YC, Lee CH, Chan TF, Wang SH, Su JH. Lower serum apelin levels in women with polycystic ovary syndrome. Fertil Steril. 2011; 95:2520–2523. 2523.e1–2523.e2.

63. Choi YS, Yang HI, Cho S, Jung JA, Jeon YE, Kim HY, et al. Serum asymmetric dimethylarginine, apelin, and tumor necrosis factor-alpha levels in non-obese women with polycystic ovary syndrome. Steroids. 2012; 77:1352–1358.

64. Tapan S, Tascilar E, Abaci A, Sonmez A, Kilic S, Erbil MK, et al. Decreased plasma apelin levels in pubertal obese children. J Pediatr Endocrinol Metab. 2010; 23:1039–1046.

65. Principe A, Melgar-Lesmes P, Fernández-Varo G, del Arbol LR, Ros J, Morales-Ruiz M, et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology. 2008; 48:1193–1201.